74 related articles for article (PubMed ID: 1490434)
21. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
22. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
23. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans.
Wallnöfer AE; van Griensven JM; Schoemaker HC; Cohen AF; Lambert W; Kluft C; Meijer P; Kooistra T
Thromb Haemost; 1993 Dec; 70(6):1005-8. PubMed ID: 8165591
[TBL] [Abstract][Full Text] [Related]
24. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass.
Chandler WL; Velan T
Thromb Res; 2003; 112(3):185-92. PubMed ID: 14967416
[TBL] [Abstract][Full Text] [Related]
25. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
26. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
[TBL] [Abstract][Full Text] [Related]
27. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
[TBL] [Abstract][Full Text] [Related]
28. Effect of a single dose of mesoglycan on the human fibrinolytic system, and the profibrinolytic action of nine daily doses.
Vittoria A; Messa GL; Frigerio C; Celasco G; Auteri A
Int J Tissue React; 1988; 10(4):261-6. PubMed ID: 2977981
[TBL] [Abstract][Full Text] [Related]
29. The plasminogen-activating system in gingival fluid from adults. An intra-individual study before and after treatment of gingivitis.
Kinnby B; Matsson L; Lecander I
Scand J Dent Res; 1994 Dec; 102(6):334-41. PubMed ID: 7871356
[TBL] [Abstract][Full Text] [Related]
30. Fibrinolytic proteins and progression of coronary artery disease in relation to gemfibrozil therapy.
Hamsten A; Syvänne M; Silveira A; Luong LA; Nieminen MS; Humphries S; Frick MH; Taskinen MR
Thromb Haemost; 2000 Mar; 83(3):397-403. PubMed ID: 10744143
[TBL] [Abstract][Full Text] [Related]
31. Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease.
Lunetta M; Salanitri T
J Int Med Res; 1992 Feb; 20(1):45-53. PubMed ID: 1568519
[TBL] [Abstract][Full Text] [Related]
32. Sex differences in the determinants of fibrinolytic activity.
MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
[TBL] [Abstract][Full Text] [Related]
33. Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis?
Gram J; Sidelmann J; Jespersen J
Thromb Haemost; 1995 Aug; 74(2):718-21. PubMed ID: 8585012
[TBL] [Abstract][Full Text] [Related]
34. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
35. [Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis].
Grabarczyk E; Szaflarska-Popławska A; Góralczyk K; Rość D
Pol Merkur Lekarski; 2006 Mar; 20(117):326-8. PubMed ID: 16780267
[TBL] [Abstract][Full Text] [Related]
36. Effect of blood passage through the pulmonary circulation on fibrinolytic parameters.
Kloboves-Prevodnik V; Sabovic M; Keber D
Heart Vessels; 2004 Jan; 19(1):33-7. PubMed ID: 14685753
[TBL] [Abstract][Full Text] [Related]
37. Pharmacodynamic effects of single and repeated doses of oral sulodexide in healthy volunteers. A placebo-controlled study with an enteric-coated formulation.
Mauro M; Palmieri GC; Palazzini E; Barbanti M; Calanni Rindina F; Milani MR
Curr Med Res Opin; 1993; 13(2):87-95. PubMed ID: 8325046
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamic Effects of Sulodexide on Profibrinolytic and Haemorrheological Patterns.
Messa GL; La Placa G; Puccetti L; Acciavatti A; Provvedi T; Palazzini E; Di Perri T
Clin Drug Investig; 1995 Sep; 10(3):165-71. PubMed ID: 27519200
[TBL] [Abstract][Full Text] [Related]
39. On the action of a heparan-like glycosaminoglycan (Hemovasal) on the mechanism of haemostasis and fibrinolysis.
Zawilska K; Elikowski W; Turowiecka Z; Zozulinska M; Grzywacz A; Przybyl L; Vinazzer H
Thromb Res; 1995 May; 78(3):211-6. PubMed ID: 7631301
[TBL] [Abstract][Full Text] [Related]
40. Double-blind, double-dummy, randomized, multi-centre clinical assessment of the efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency.
Saviano M; Maleti O; Liguori L
Curr Med Res Opin; 1993; 13(2):96-108. PubMed ID: 8325047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
